ArticleImmunity, inflammation and disease2026
The Impact of Surfactant Protein-D Gene Polymorphism on COVID-19 Clinical Outcomes.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surfactant-Associated Protein D Polymorphism and Protection Against COVID-19 in the Czech Population.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCOVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents a broad spectrum of clinical manifestations, ranging from asymptomatic cases to severe, life-threatening respiratory complications. Pulmonary surfactant-associated protein D (SP-D) is a critical component of pulmonary immune defense. The objective of this study was to investigate the association between a specific single-nucleotide polymorphism (SNP) in the SP-D gene, designated as rs721917 (C/T Met31Thr), and its potential impact on susceptibility to and severity of COVID-19.
methodsThis retrospective case-control study enrolled 135 participants, including 111 confirmed COVID-19 patients and 24 asymptomatic or presymptomatic individuals, who were classified into five subgroups. Addressing a significant research gap, we identified the C/T polymorphism (rs721917, T > C) of the SP-D gene within the Iranian population using the tetra-amplification refractory mutation system polymerase chain reaction (T-ARMS PCR) method.
resultsStatistical analysis showed a significant association between the SP-D rs721917 TT genotype and T allele with increased COVID-19 severity and hospitalization risk. The TT genotype was more frequent in ICU and CCU-admitted patients compared to the CC genotype (p < 0.05) and was linked to higher hospitalization rates overall. However, no significant correlation was found with mortality rates or patients' age.
conclusionThese findings suggest that variations at the rs721917 locus within the SFTPD gene may provide valuable insights into the heterogeneity of COVID-19 outcomes across different populations, thereby offering potential for enhanced diagnostic and prognostic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.